Cessation Therapeutics Presents Findings From Anti-Fentanyl Study
19 Jun 2024 //
BUSINESSWIRE
Cessation Therapeutics Receives FDA Fast Track Designation for CSX-1004
31 Oct 2023 //
BUSINESSWIRE
Cessation Awarded $14.8 Million Grant from the National Institute of Drug Abuse
18 Oct 2023 //
BUSINESSWIRE
Cessation Announces FDA Authorization for First-in-Human Trial of Antibody
27 Jul 2023 //
BUSINESSWIRE